AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39443954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (standard treatment for sepsis plus enteral ivabradine)
Number of subjects: 172
Study 39443954 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (GS)
Number of subjects: 172
Study 39443954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (GI)
Number of subjects: 172
Study 39443965 — intervention group
Group type: EXPERIMENTAL
Intervention: New General Self Efficacy Scale (NGSES)
Number of subjects: 121
Study 39443991 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction models including omics data (proteins and microRNAs)
Number of subjects: 231
Study 39443991 — intervention group
Group type: COMPARATOR
Intervention: Models based on demographics alone
Number of subjects: 231
Study 39443991 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood biomarkers (surfactant protein-D, serine protease inhibitor A7, MMP-9)
Number of subjects: 231
Study 39443991 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood biomarkers (CC motif chemokine 11, vascular cell adhesion protein-1, adiponectin, carcinoembryonic antigen, MMP-9)
Number of subjects: 231
Study 39444003 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (low tourniquet pressure, LOP + 50 mmHg)
Number of subjects: 24
Study 39444003 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (high tourniquet pressure, LOP + 100 mmHg)
Number of subjects: 24
Study 39444031 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training program for clinical staff
Number of subjects: 1601
Study 39444037 — intervention group
Group type: COMPARATOR
Intervention: AL002 (single intravenous infusion)
Number of subjects: 64
Study 39444037 — intervention group
Group type: EXPERIMENTAL
Intervention: AL002 (weekly intravenous injections for 4 weeks in cynomolgus monkeys)
Number of subjects: 64
Study 39444039 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline based chemotherapy
Number of subjects: 0
Study 39444039 — intervention group
Group type: EXPERIMENTAL
Intervention: High immune infiltration (CD8+ T cells and CD20+ B cells)
Number of subjects: 0
Study 39444039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing clinical trials combining chemotherapy with immune checkpoint inhibitors
Number of subjects: 0
Study 39444044 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole foods diet intervention (2020-2025 Dietary Guidelines for Americans adapted whole foods diet)
Number of subjects: 20
Study 39444044 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole foods diet intervention
Number of subjects: 20
Study 39444052 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel monotherapy (3.75 mg/day)
Number of subjects: 2715
Study 39444052 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) with prasugrel and aspirin
Number of subjects: 2715
Study 39444052 — intervention group
Group type: EXPERIMENTAL
Intervention: No-aspirin group
Number of subjects: 2715
Study 39444052 — intervention group
Group type: COMPARATOR
Intervention: DAPT group
Number of subjects: 2715
Study 39444331 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation Advisor (EA) tool implementation
Number of subjects: 31
Study 39444331 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews with critical care physicians (MDs) and respiratory therapists (RTs)
Number of subjects: 31
Study 39444331 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived benefit of EA tool use
Number of subjects: 31
Study 39444552 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission glucose (AG) levels
Number of subjects: 1705
Study 39444571 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine milk-based infant formula with added bovine MFGM (5 g/L) for 60 days
Number of subjects: 3
Study 39444571 — intervention group
Group type: COMPARATOR
Intervention: Bovine milk-based infant formula (Control) for 60 days
Number of subjects: 3
Study 39444571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's own human milk (HM) for 60 days
Number of subjects: 3
Study 39444874 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative blood ctDNA somatic mutation/methylation alone or combined with PET-CT
Number of subjects: 200
Study 39444874 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA somatic mutation/methylation profiles alone or combined with PET-CT
Number of subjects: 200
Study 39444874 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative negative ctDNA profiling and/or PET-CT
Number of subjects: 200
Study 39444881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resection for AIS and MIA diagnosed by FS
Number of subjects: 390
Study 39444901 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring of home NIV (T4P device, SRETT, Paris, France) for 3 months
Number of subjects: 0
Study 39444901 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 39445112 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary Interleukin-1
Number of subjects: 0
Study 39445319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at baseline, Week 4, and every 12 weeks thereafter to Week 52, with final assessment at Week 64.
Number of subjects: 55
Study 39445319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab treatment
Number of subjects: 55
Study 39445322 — intervention group
Group type: EXPERIMENTAL
Intervention: E-BPO cream, 5%
Number of subjects: 733
Study 39445322 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 733
Study 39445322 — intervention group
Group type: EXPERIMENTAL
Intervention: E-BPO cream, 5% (subjects <65)
Number of subjects: 733
Study 39445322 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (subjects <65)
Number of subjects: 733
Study 39445322 — intervention group
Group type: EXPERIMENTAL
Intervention: E-BPO cream, 5% (subjects ≥65)
Number of subjects: 733
Study 39445322 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (subjects ≥65)
Number of subjects: 733
Study 39445416 — intervention group
Group type: EXPERIMENTAL
Intervention: DK crush
Number of subjects: 202
Study 39445416 — intervention group
Group type: COMPARATOR
Intervention: DK culotte
Number of subjects: 202
Study 39445439 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA neomer profiling at TP1
Number of subjects: 44
Study 39445439 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA neomer profiling at TP2
Number of subjects: 44
Study 39445439 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA neomer profiling at TP3
Number of subjects: 44
Study 39445439 — intervention group
Group type: COMPARATOR
Intervention: ctDNA mutation-based results at TP1
Number of subjects: 44
Study 39445439 — intervention group
Group type: COMPARATOR
Intervention: ctDNA mutation-based results at TP3
Number of subjects: 44
Study 39445439 — intervention group
Group type: COMPARATOR
Intervention: ctDNA mutation-based method at TP1
Number of subjects: 44
Study 39445439 — intervention group
Group type: EXPERIMENTAL
Intervention: combination results
Number of subjects: 44
Study 39445439 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of neomer and ctDNA mutation-based results
Number of subjects: 44
Study 39445512 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider surgical intervention (86% of children, 49% of adults)
Number of subjects: 304
Study 39445512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasers (CO2 laser)
Number of subjects: 304
Study 39445570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical ripening with a double balloon device for 6 hours
Number of subjects: 67
Study 39445570 — intervention group
Group type: COMPARATOR
Intervention: Cervical ripening with a double balloon device for 12 hours
Number of subjects: 67
Study 39445609 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril/amlodipine 4/5 mg
Number of subjects: 440
Study 39445609 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril/amlodipine/indapamide 4/5/1.25 mg
Number of subjects: 440
Study 39445704 — intervention group
Group type: EXPERIMENTAL
Intervention: NTLA-2002 25 mg
Number of subjects: 27
Study 39445704 — intervention group
Group type: EXPERIMENTAL
Intervention: NTLA-2002 50 mg
Number of subjects: 27
Study 39445704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 39445764 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC burden >5%
Number of subjects: 6529
Study 39445764 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC burden >10%
Number of subjects: 6529
Study 39445764 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC burden 5.1%-10%
Number of subjects: 6529
Study 39445764 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC >5%
Number of subjects: 6529
Study 39445764 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC >5% and LVEF <50%
Number of subjects: 6529
Study 39445764 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 6529
Study 39445776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg
Number of subjects: 4
Study 39445776 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib 4 mg
Number of subjects: 4
Study 39445776 — intervention group
Group type: EXPERIMENTAL
Intervention: Unanchored population-adjusted ITC
Number of subjects: 4
Study 39445810 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-creation workshops and in-depth interviews with healthcare providers
Number of subjects: 0
Study 39445855 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Protocol
Number of subjects: 0
Study 39445855 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39445920 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health problems at 3 months (n = 3368)
Number of subjects: 4092
Study 39445920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive health problems at 3 months (n = 3368)
Number of subjects: 4092
Study 39445920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health problems at 3 months (n = 3368)
Number of subjects: 4092
Study 39445920 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health problems at 12 months (n = 2950)
Number of subjects: 4092
Study 39445920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive health problems at 12 months (n = 2950)
Number of subjects: 4092
Study 39445920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health problems at 12 months (n = 2950)
Number of subjects: 4092
Study 39446087 — intervention group
Group type: EXPERIMENTAL
Intervention: UGN-102 (mitomycin), 6 weekly intravesical instillations
Number of subjects: 240
Study 39446325 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous RZV and aIIV4
Number of subjects: 267
Study 39446325 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous RZV and HD-IIV4
Number of subjects: 267
Study 39446327 — intervention group
Group type: EXPERIMENTAL
Intervention: RT twice daily to a dosage of 45 Gy for 3 weeks
Number of subjects: 638
Study 39446327 — intervention group
Group type: COMPARATOR
Intervention: RT once daily to a dosage of 70 Gy for 7 weeks
Number of subjects: 638
Study 39446327 — intervention group
Group type: EXPERIMENTAL
Intervention: N2 disease
Number of subjects: 638
Study 39446327 — intervention group
Group type: EXPERIMENTAL
Intervention: N3 disease
Number of subjects: 638
Study 39446327 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IIIA cancer
Number of subjects: 638
Study 39446327 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IIIB cancer
Number of subjects: 638
Study 39446327 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume accrual centers
Number of subjects: 638
Study 39446327 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-volume accrual centers
Number of subjects: 638
Study 39446365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nivolumab, 3 mg/kg, every 2 weeks and ipilimumab, 1 mg/kg, every 6 weeks until disease progression, intolerable adverse events, or a maximum duration of 2 years.
Number of subjects: 49
Study 39446377 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1: Vemurafenib plus cobimetinib plus atezolizumab
Number of subjects: 43
Study 39446377 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2: Cobimetinib plus atezolizumab
Number of subjects: 43
Study 39446377 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 3: Bevacizumab plus atezolizumab
Number of subjects: 43
Study 39446377 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall targeted therapy cohort
Number of subjects: 43
Study 39446378 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome sequencing for early-onset genetic conditions with established interventions
Number of subjects: 4000
Study 39446378 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome sequencing for neurodevelopmental disorders associated with seizures (optional)
Number of subjects: 4000
Study 39446378 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment in genomic NBS study
Number of subjects: 4000
Study 39446432 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprexis intervention
Number of subjects: 132
Study 39446432 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 132
Study 39446605 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX07 monotherapy (1,000 mg IV Q2W)
Number of subjects: 50
Study 39446605 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX07 combined with serplulimab (200 mg IV day 1) and cisplatin (50 mg/m2)
Number of subjects: 50
Study 39446647 — intervention group
Group type: EXPERIMENTAL
Intervention: ARSB fading intervention
Number of subjects: 0
Study 39446647 — intervention group
Group type: EXPERIMENTAL
Intervention: UHB fading condition
Number of subjects: 0
Study 39446648 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral sex therapy (iCBST)
Number of subjects: 266
Study 39446648 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based mindfulness-based sex therapy (iMBST)
Number of subjects: 266
Study 39446648 — intervention group
Group type: COMPARATOR
Intervention: waitlist control group
Number of subjects: 266
Study 39446736 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sacrospinous vaginal vault fixation with synthetic mesh arms (BSSVF-M)
Number of subjects: 358
Study 39446736 — intervention group
Group type: COMPARATOR
Intervention: Standard sacrospinous ligament suspension with sutures (SSLS)
Number of subjects: 358
Study 39446736 — intervention group
Group type: EXPERIMENTAL
Intervention: BSSVF-M
Number of subjects: 358
Study 39446746 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated directly observed therapy (DOT)
Number of subjects: 72
Study 39446746 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated self-administered therapy (SAT)
Number of subjects: 72
Study 39446746 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient choice between facilitated DOT and facilitated SAT
Number of subjects: 72
Study 39446746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP completion strategies
Number of subjects: 72
Study 39446746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP delivery strategies
Number of subjects: 72
Study 39446746 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and care integration
Number of subjects: 72
Study 39446746 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 treatment disruptions
Number of subjects: 72
Study 39446746 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs of 3HP facilitation
Number of subjects: 72
Study 39446767 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful interoceptive exposure using a 2-minute attention exercise guided by a smartphone app over 8 weeks
Number of subjects: 31
Study 39446982 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention within less than 24 hours, especially in the cervical spine
Number of subjects: 0
Study 39446982 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure goals and steroids to maintain perfusion and decrease secondary injury
Number of subjects: 0
Study 39447049 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance of instrumental activities of daily living (Lawton and Brody scale)
Number of subjects: 102
Study 39447049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependence on activities of daily living (Barthel scale)
Number of subjects: 102
Study 39447049 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint damage (Hemophilia Joint Health Score)
Number of subjects: 102
Study 39447049 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 102
Study 39447049 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 102
Study 39447048 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1800
Study 39447048 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous intervention (PCI)
Number of subjects: 1800
Study 39447048 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score II-2020
Number of subjects: 1800
Study 39447053 — intervention group
Group type: EXPERIMENTAL
Intervention: F2 antigen plus AS01 adjuvant
Number of subjects: 130
Study 39447053 — intervention group
Group type: EXPERIMENTAL
Intervention: F2 antigen
Number of subjects: 130
Study 39447053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 39447053 — intervention group
Group type: EXPERIMENTAL
Intervention: F2 antigen or F2 antigen plus AS01 adjuvant (third dose)
Number of subjects: 130
Study 39447094 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 90
Study 39447170 — intervention group
Group type: EXPERIMENTAL
Intervention: Be-Prox intervention (6 modules over a 9-month period)
Number of subjects: 708
Study 39447170 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention during the study period)
Number of subjects: 708
Study 39447384 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal stress responses during the still-face paradigm (FFSF-R)
Number of subjects: 31
Study 39447384 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant stress responses during the still-face paradigm (FFSF-R)
Number of subjects: 31
Study 39447384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-infant synchrony during the still-face paradigm (FFSF-R)
Number of subjects: 31
Study 39447517 — intervention group
Group type: EXPERIMENTAL
Intervention: SG001 240 mg every two weeks for 24 months or until disease progression, intolerable toxicities, or other study discontinuation criteria were met.
Number of subjects: 107
Study 39447530 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (1-2 post-tetanic count) with repeated boluses of rocuronium
Number of subjects: 100
Study 39447530 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (1-3 train of four response) with repeated boluses of rocuronium
Number of subjects: 100
Study 39447587 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma symptoms in adolescents with no clinical diagnosis of asthma
Number of subjects: 27272
Study 39447587 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive asthma tests in undiagnosed adolescents with severe symptoms
Number of subjects: 27272
Study 39447587 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma symptoms in adolescents with clinician-diagnosed asthma
Number of subjects: 27272
Study 39447587 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of asthma medication in adolescents with severe symptoms
Number of subjects: 27272
Study 39447587 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of asthma symptoms across different locations
Number of subjects: 27272
Study 39447676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent calorie restriction (ICR) - 2 successive days of fasting (∼500 kcal/d) and 5 days of recovery per week
Number of subjects: 60
Study 39447676 — intervention group
Group type: COMPARATOR
Intervention: Continuous calorie restriction (CCR)
Number of subjects: 60
Study 39447676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent calorie restriction (ICR)
Number of subjects: 60
Study 39447717 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective invasive management guided by ischemia stress imaging (IMG group)
Number of subjects: 1756
Study 39447717 — intervention group
Group type: COMPARATOR
Intervention: Routine invasive strategy (INV group)
Number of subjects: 1756
Study 39447716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pumping (IABP) as an adjunct to veno-arterial (V-A) ECMO
Number of subjects: 0
Study 39447716 — intervention group
Group type: COMPARATOR
Intervention: V-A ECMO alone
Number of subjects: 0
Study 39447813 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF-guided source ablation
Number of subjects: 85
Study 39447813 — intervention group
Group type: COMPARATOR
Intervention: PVI only (for patients with EGF-identified sources)
Number of subjects: 85
Study 39447813 — intervention group
Group type: COMPARATOR
Intervention: PVI only (for patients with no sources)
Number of subjects: 85
Study 39447871 — intervention group
Group type: EXPERIMENTAL
Intervention: Port Delivery System with ranibizumab (100 mg/mL) Q24W
Number of subjects: 418
Study 39447871 — intervention group
Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab (0.5 mg)
Number of subjects: 418
Study 39448029 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 (infliximab biosimilar)
Number of subjects: 751
Study 39448057 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 868
Study 39448077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral iTBS at 60-min intervals
Number of subjects: 182
Study 39448077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral iTBS at 30-min intervals
Number of subjects: 182
Study 39448077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral iTBS at 0-min intervals (once-daily)
Number of subjects: 182
Study 39448077 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 182
Study 39448200 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab (n=23)
Number of subjects: 44
Study 39448200 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab+ipilimumab (n=21)
Number of subjects: 44
Study 39448200 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumors with actionable genomic alterations (AGAs, n=12)
Number of subjects: 44
Study 39448200 — intervention group
Group type: COMPARATOR
Intervention: Tumors without actionable genomic alterations (non-AGAs)
Number of subjects: 44